ASX · HMD.AX
HeraMED Limited
A$0.04+A$0.00 (+8.82%)
HeraMED Limited’s quoted price sits in the lower half of its reported 52-week range, 32.73% below the high.
Loading market information…
ASX · RHT.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 04:58 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Resonance Health Limited’s quoted price sits in the upper half of its reported 52-week range, 13.95% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Resonance Health Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Resonance Health Limited is a global provider of healthcare technology and services, specializing in the design, development, and production of software-as-medical devices. The company serves markets across the Asia Pacific, Americas, Europe, Middle East, and Africa. Its portfolio of non-invasive, MRI-based diagnostic tools includes FerriScan, a system for quantifying liver iron concentration (LIC); FerriSmart, leveraging artificial intelligence (AI) for automated, real-time assessment of LIC; HepaFat-AI, an AI-driven solution for real-time, multi-metric liver fat quantification; CardiacT2, which provides dual analysis in conjunction with FerriScan to evaluate cardiac iron accumulation; HepaFat-Scan, a non-invasive MRI method for assessing liver fat within tissue; and LiverSmart, a comprehensive non-invasive MRI device integrating FerriSmart and HepaFat-AI for a unified report. The company further extends its offerings to include quantitative imaging measurements and Contract Research Organization (CRO) services, encompassing rigorous image analysis, imaging charter development, robust project and data management, proactive issue resolution, site tracking with clinical trial progress reports, and streamlined data flow coordination. They also provide comprehensive biomarker services, covering analysis of blood, urine, and protein analytes, alongside RNA, DNA, and genotyping. Their support for multinational and multicenter clinical trials extends to protocol development, subject inclusion/exclusion criteria assessment, dose modification strategies, new therapy safety profile evaluations, and establishing primary and secondary endpoints for drug efficacy. Additionally, they supply phantoms crucial for MRI machine calibration. Its client base includes clinicians, who utilize their solutions for managing human diseases, and pharmaceutical and therapeutic companies engaged in clinical research. Established in 1987, Resonance Health Limited maintains its headquarters in Burswood, Australia.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:19 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.04+A$0.00 (+8.82%)
HeraMED Limited’s quoted price sits in the lower half of its reported 52-week range, 32.73% below the high.
A$0.02+A$0.00 (+5.88%)
Neurotech International Limited’s quoted price sits in the upper half of its reported 52-week range, 14.29% below the high.
A$0.04-A$0.00 (-2.22%)
IDT Australia Limited’s quoted price sits in the lower half of its reported 52-week range, 29.03% below the high.
A$0.35+A$0.02 (+4.55%)
ImExHS Limited’s quoted price sits in the lower half of its reported 52-week range, 26.6% below the high.
A$0.02A$0.00 (0.0%)
Intelicare Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 37.5% below the high.
A$0.02A$0.00 (0.0%)
MedAdvisor Limited’s quoted price sits in the lower half of its reported 52-week range, 93.02% below the high.
A$0.01-A$0.00 (-6.67%)
Atomo Diagnostics Limited’s quoted price sits in the lower half of its reported 52-week range, 70.83% below the high.
A$0.04A$0.00 (0.0%)
Immuron Limited’s quoted price sits in the lower half of its reported 52-week range, 59.18% below the high.
